LOGO
LOGO

TENX Hits 52-Week High As Clinical Progress Gains Momentum

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
tenx 25112025 lt

Tenax Therapeutics Inc. (TENX) has garnered attention due to recent corporate and clinical developments that underscore advancements in its late-stage pipeline.

The company is advancing levosimendan, a first-in-class K-ATP channel activator and calcium sensitizer, for the treatment of pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This condition remains a significant unmet medical need, with no approved therapies currently available.

Subscribe to continue reading the article.
This article is available exclusively to RTT Biotech Investor and Intelligent Investor subscribers. Subscribe with a RTTNews subscription.
Start Free Trial
FREE 7-Day Trial - No Payment Required
Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Global Economics Weekly Update - Jun 08-12, 2026

June 12, 2026 17:14 ET
Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.